GSK plc (LON:GSK – Get Free Report) has earned an average rating of “Moderate Buy” from the seven research firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is GBX 1,791.25 ($22.72).
Several equities analysts recently issued reports on the company. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,100 ($26.64) price objective on shares of GSK in a report on Thursday. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a GBX 1,950 ($24.74) price objective on shares of GSK in a research report on Friday. JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a report on Tuesday, June 18th. Barclays reaffirmed an “equal weight” rating and issued a GBX 1,725 ($21.88) price target on shares of GSK in a report on Tuesday, May 7th. Finally, Citigroup reissued a “buy” rating and set a GBX 2,100 ($26.64) price objective on shares of GSK in a research note on Monday, June 24th.
Check Out Our Latest Stock Report on GSK
GSK Stock Up 0.2 %
GSK Cuts Dividend
The company also recently declared a dividend, which will be paid on Thursday, July 11th. Stockholders of record on Thursday, May 16th will be given a dividend of GBX 15 ($0.19) per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a dividend yield of 0.9%. GSK’s dividend payout ratio is currently 5,504.59%.
Insider Buying and Selling at GSK
In other news, insider Wendy Becker purchased 446 shares of the stock in a transaction dated Thursday, June 20th. The shares were bought at an average cost of GBX 1,614 ($20.47) per share, for a total transaction of £7,198.44 ($9,131.60). 1.60% of the stock is owned by company insiders.
GSK Company Profile
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
See Also
- Five stocks we like better than GSK
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- How is Compound Interest Calculated?
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.